Northern Trust’s enGene Therapeutics ENGN Stock Holding History

Northern Trust’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$205K	Hold	30,085	–	–	﹤0.01%	3946
2025 Q4	$272K	Sell	30,085 -210	-0.7%	-$1.68K	﹤0.01%	3870
2025 Q3	$207K	Sell	30,295 -2,731	-8%	-$12.5K	﹤0.01%	3970
2025 Q2	$120K	Sell	33,026 -816	-2%	-$3.06K	﹤0.01%	4072
2025 Q1	$152K	Sell	33,842 -574	-2%	-$3.56K	﹤0.01%	4016
2024 Q4	$229K	Hold	34,416	–	–	﹤0.01%	3944
2024 Q3	$227K	Buy	+34,416	New	+$256K	﹤0.01%	3842

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Northern Trust's ENGN Position: Q1 2026 in Review

Northern Trust held its enGene Therapeutics (ENGN) position steady in Q1 2026 at 30,085 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #3946.

Northern Trust first reported a position in ENGN in Q3 2024 and has held it in 7 quarters since. The position peaked at $272K in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

Northern Trust held 30,085 shares of enGene Therapeutics worth $205K as of Q1 2026.
Northern Trust left its enGene Therapeutics share count unchanged in Q1 2026.
enGene Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3946 holding.
Northern Trust first reported a position in enGene Therapeutics in Q3 2024 and has held it in 7 quarters since.
Northern Trust's enGene Therapeutics position peaked at $272K in Q4 2025.
61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.